Nxera Pharma Reports Third-Quarter 2026 Operational Highlights and Results
Nxera Pharma announced operational highlights and consolidated results for the third quarter of 2026.
Story updates
06:37:22 AM UTC
SquawkNews
Nxera Pharma reported Q3 2026 consolidated results and said it earned a $10M milestone from Neurocrine and a $8.6M milestone from the OX2R program originated with Centessa, now part of Lilly. It also filed a MAA in South Korea for vamorolone for DMD.Material DetailsContext by AI AnalystThis sits mi…